Jan-Anders Christer Mellberg

Quantovir AB conducts research and development of methods for cancer diagnostics and related business. It develops technology for quantitative measurement of high-risk Human Papillomavirus (HPV) types using deoxyribonucleic acid (DNA)-based detection. It demonstrates that a molecular diagnostic test measuring the quantity, or viral load, of HPV DNA present in cervical specimens can be used to predict a woman's risk of developing cervical cancer. The company was founded by Ulf Gyllensten on February 28, 2001 and is headquartered in Uppsala, Sweden.

Visionar Preclinical AB is a CRO specialized on in vivo preclinical contract research and services. The company was founded year 2000 by individuals with extensive experience of preclinical research and development in international pharmaceutical companies. Its customers are small and mid-size companies who work with drugs, biopharmaceuticals, or medical devices. Quality and flexibility are key factors in their work. Its extensive experience makes it possible for them to find unconventional solutions to preclinical matters. It work closely with their Sponsors to develop strategies for cost effective evaluation of drug candidates and to perform necessary regulatory studies for phase I-II clinical trials.

Noster System AB developed and marketed respiratory analysis systems. It developed a diagnostic aid for analyzing the occurrence of heliobacter polyri in the stomach. The company was located in Stockholm, Sweden.

Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden.